2024 Grant Report
|
Year |
Amount |
Center |
Researcher |
Grant Name |
Category |
Type of Cancer |
Subtype |
|
2024 |
$125,000 |
Texas Children’s Cancer Center |
Dr. Carl Allen |
Defining Cell(s) of Origin and Clinical Risk in Langerhans Cell Histiocytosis |
Langerhans Cell Histiocytosis |
||
|
2024 |
$125,000 |
St. Jude Children’s Research Hospital |
Dr. Sara Federico |
HuNB803: A Safety Run-in and Phase 2 Randomized Trial of Chemoimmunotherapy Administered With and Without N-803, A Novel IL-15 Superagonist, for the Treatment of Patients With Relapsed or Refractory Neuroblastoma |
Solid and Bone Cancers |
Neuroblastoma |
|
|
2024 |
$200,000 |
Memorial Sloan Kettering |
Dr. Jason Lewis |
Radiotherapeutic Targeting of Developmental Mutators in Childhood Solid Tumors as a Prelude to a New Clinical Trial for Children with Neuroblastomas and Other DLL3 Solid Tumors |
Solid and Bone Cancers |
Solid Tumors |
|
|
2024 |
$200,000 |
Texas Children’s Cancer Center |
Dr. Leonid Metelitsa |
Developing Cytokine-armed CAR-NKT Immunotherapy for Neuroblastoma |
Solid and Bone Cancers |
Neuroblastoma |
|
|
2024 |
$200,000 |
Seattle Children’s Hospital |
Dr. Mignon Loh |
Testing an Immunotherapy Drug/Molecule for Dual Recognition and Attachment to CD19 and CD33 Markers on MPAL Cancer Cells |
Blood Cancer |
Leukemia |
Mixed-Phenotype Acute Leukemia (MPAL) |
|
2024 |
$200,000 |
Dana-Farber Cancer Institute |
Dr. Thomas Look |
KAT6A/B Inhibitor Plus Isotretinoin and Anti-GD2 for High-Risk Neuroblastoma |
Solid and Bone Cancers |
Neuroblastoma |
|
|
2024 |
$200,000 |
University of California San Francisco Benioff Children’s Hospital |
Dr. Arun Wiita |
Optimized Anti-CD70 CAR-NK Cells for the Treatment of Pediatric Acute Myeloid Leukemia |
Blood Cancer |
Leukemia |
Acute Myeloid Leukemia (AML) |
|
2023 & 2024 |
$100,000 |
Dana-Farber Cancer Institute |
Dr. Scott Armstrong |
Targeting Chromatin Complexes in NUP98-rearranged AML |
Blood Cancer |
Leukemia |
Acute Myeloid Leukemia (AML) |
|
2023 & 2024 |
$100,000 |
Memorial Sloan Kettering |
Dr. Nai-Kong Cheung |
Enhancing the Efficacy of GD2 Cancer Vaccine for High-risk Neuroblastoma by Augmenting Seroconversion |
Solid and Bone Cancers |
Neuroblastoma |
|
|
2023 & 2024 |
$100,000 |
Texas Children’s Cancer Center |
Dr. Meenakshi Hegde |
Multi-center Clinical Testing of Autologous HER2 CAR T Cells and its Synergy with Surgical Resection in Recurrent Ependymoma |
Brain Tumors |
Ependymoma |
|
|
2024 |
$350,000 |
Texas Children’s Cancer Center |
Dr. Hedge |
Provide Funding for Children on Trial Waiting List |
Brain Tumors |
Ependymoma |
|
|
2023 & 2024 |
$100,000 |
Children’s Hospital of Philadelphia |
Dr. John M. Maris |
Functional Characterization and Armoring of Peptide-centric CAR T Cells to Enhance Efficacy |
Solid and Bone Cancers |
Neuroblastoma |
|
|
2023 & 2024 |
$100,000 |
University of California San Francisco Benioff Children’s Hospital |
Dr. Ross Okimoto |
Exploiting DNA Repair Mechanisms to Overcome CIC-DUX4 Sarcoma |
Solid and Bone Cancers |
CIC-DUX4 Sarcoma |
|
|
2023 & 2024 |
$100,000 |
Seattle Children’s Hospital |
Dr. Jim Olson |
Antigen Assimilating Multispecific T Cell Engagers (MTEs) for the Treatment of Diffuse Midline Glioma (DMG) |
Brain Tumors |
Diffuse Midline Gliomas (DMG) |
|
|
2023 & 2024 |
$100,000 |
St. Jude Children’s Research Hospital |
Dr. Elizabeth Stewart |
Evaluation of PARP1 Selective Inhibitor AZD5305 in Combination with DNA Damaging Agents in Ewing Sarcoma |
Solid and Bone Cancers |
Ewing Sarcoma |